Apply for Letairis (Ambrisentan) Copay Assistance

Ambrisentan copay assistance means outside financial help that can lower what you pay for Letairis or generic ambrisentan. Depending on your insurance, that help may come from a manufacturer copay program or a grant from an independent nonprofit foundation.*

QuickRx Specialty Pharmacy does the legwork for you. Our patient navigators check your insurance, look for the options you may qualify for, prepare and submit the applications on your behalf, and keep track of renewals, at no cost to you.*

To get started, call QuickRx at (917) 830-2525 or complete the form on this page.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Some manufacturers offer copay programs for patients with commercial insurance, and the options can differ between brand Letairis and the different generic versions of ambrisentan. Eligible patients may pay $0.*

QuickRx checks which programs match the version of ambrisentan you are prescribed and applies on your behalf. Call (917) 830-2525.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Each program sets its own rules. Manufacturer copay programs are generally limited to patients with commercial or private insurance, and generally cannot be used by patients whose prescription is paid for by Medicare, Medicaid or other federal health care programs.

Patients with Medicare or other government insurance may still have options, such as an independent foundation grant for pulmonary arterial hypertension (PAH) when funds are open.*

QuickRx reviews your situation and tells you which options you may qualify for. Call (917) 830-2525.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Medicare patients cannot use manufacturer copay programs. Other help may still be available, such as independent foundation grants for PAH, Extra Help (the Low-Income Subsidy) for patients who qualify, and state pharmaceutical assistance programs in some states.*

In 2026, Medicare Part D caps yearly out-of-pocket drug costs at $2,100 (PAN Foundation). The Medicare Prescription Payment Plan can also spread those costs into monthly payments.

QuickRx can review your Part D coverage and look for options at no cost to you. Call (917) 830-2525.

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

No. There is never any cost for QuickRx’s copay assistance services. You will not receive a bill from QuickRx for checking your eligibility, preparing applications or handling renewals.*

*Eligibility, benefit amounts and availability are set by each manufacturer or foundation, not by QuickRx. Not all patients qualify, and programs may change or close without notice. QuickRx does not issue copay cards; we apply on your behalf.

Yes. Generic ambrisentan is available in the United States in the same 5 mg and 10 mg tablet strengths as brand Letairis.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026), Generic Available (US) and Dosage Forms: US.

Yes. QuickRx Specialty Pharmacy dispenses ambrisentan and is licensed in all 50 states, with free home delivery. Our team also helps with prior authorization and copay assistance. Learn more about our nationwide delivery, or call (917) 830-2525.

Ambrisentan treats pulmonary arterial hypertension (PAH, WHO Group 1), a type of high blood pressure in the arteries of the lungs. It is used in adults to improve exercise ability and delay the disease from getting worse.

It is also used together with tadalafil to lower the risk of PAH getting worse and of hospital stays for worsening PAH, and to improve exercise ability. Ambrisentan is an endothelin receptor antagonist: it blocks endothelin, a substance that narrows blood vessels.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

The usual starting dose is 5 mg by mouth once a day. Your doctor may increase it to 10 mg once a day after about 4 weeks if you tolerate it well.

Swallow the tablet whole, with or without food. Do not split, crush or chew it. Always follow the exact dose your PAH specialist gives you.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

Ambrisentan has a boxed warning, the FDA’s strongest warning, because it may cause major birth defects. It must not be used during pregnancy.

Patients who could become pregnant need a negative pregnancy test before starting, and must use effective birth control before starting, during treatment and for 1 month after the last dose. Pregnancy testing is repeated if a period is late or pregnancy is suspected. If pregnancy happens, ambrisentan is stopped as soon as possible.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

Ambrisentan should not be used by people who are pregnant, or by people with idiopathic pulmonary fibrosis (IPF), including IPF with pulmonary hypertension (WHO Group 3).

It is not recommended for people with moderate or severe liver problems, or for people with significant anemia.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

Common side effects include swelling of the legs, ankles or feet (17% to 38%), headache (34%), cough (13%) and stuffy nose (6% to 16%). Less common side effects include flushing, upset stomach, low red blood cells (anemia), bronchitis and sinus infection.

Tell your doctor about any side effects that bother you or do not go away.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

Fluid retention: swelling, weight gain or new or worse trouble breathing can happen, sometimes needing treatment or a hospital stay. Swelling is more common in older adults and with tadalafil.

Lower red blood cells: hemoglobin can drop in the first few weeks. Your care team checks it before you start, at 1 month and from time to time after that.

Liver problems: call your doctor right away for dark urine, light-colored stools, stomach pain, throwing up or yellow skin or eyes.

Fluid in the lungs (PVOD): if fluid builds up in the lungs, your doctor will stop ambrisentan.

Ambrisentan may also lower sperm counts.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

Yes. Cyclosporine can raise ambrisentan levels, so the ambrisentan dose is limited to 5 mg a day for patients taking cyclosporine. Sparsentan and leniolisib should be avoided with ambrisentan. Several other medicines may raise ambrisentan levels and need monitoring.

Tell every doctor and pharmacist about every medicine, supplement and herbal product you take. QuickRx pharmacists can review your list; call (917) 830-2525.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

Your care team will check your hemoglobin before you start, at 1 month and periodically during treatment, watch for swelling and fluid retention, and check liver tests when needed. Patients who could become pregnant need a pregnancy test before starting.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

Kidney problems: no dose change is needed for most patients, because ambrisentan is mainly cleared outside the kidneys.

Liver problems: exposure may be higher with mild liver problems, and use is not recommended with moderate or severe liver problems. If liver enzymes rise above 5 times normal, or rise with signs of liver injury, ambrisentan is stopped.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.

Store ambrisentan at room temperature, 25°C (77°F), in its original packaging. Short trips between 15°C and 30°C (59°F to 86°F) are allowed.

Source: Lexidrug, ambrisentan monograph (Last Updated September 28, 2026; accessed November 11, 2026); Letairis (ambrisentan) FDA prescribing information. This is not a complete list. Do not start, stop or change how you take ambrisentan without talking to your PAH specialist.